Summary
This prediction ended on 07.06.18 with a price of €27,600,000. With a performance of -9.21%, the BUY prediction for Neovacs by melinda closed slightly in the red. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Neovacs | - | - | - | - |
| iShares Core DAX® | 1.301% | -1.386% | 12.259% | 59.752% |
| iShares Nasdaq 100 | 0.612% | -4.172% | 1.687% | 86.147% |
| iShares Nikkei 225® | 8.772% | 9.777% | 30.041% | 63.047% |
| iShares S&P 500 | 0.254% | -2.301% | 0.794% | 57.981% |
According to melinda what are the pros and cons of Neovacs for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Neovacs diskutieren
Neovacs: Beginn der Spekulation vor klinischen Ergebnissen für LUPUS?
